Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.